Here's a concise, retail-friendly summary for Camlin Fine Sciences: **Camlin Fine Sciences Q2/H1 FY26 Recap:** Revenue climbed 10.2% YoY to Rs 459.8 Cr for Q2, and 10.7% YoY for H1 to Rs 883.4 Cr.

Adjusted EBITDA hit Rs 33.4 Cr (7.3% margin) in Q2. Significant win: Continuing operations losses (PBT) narrowed sharply to just Rs 0.1 Cr from Rs 4.3 Cr QoQ!

Total PAT, including discontinued units, also improved to a loss of Rs 14.95 Cr from Rs 116.11 Cr last year. **Growth & Strategy:** Blends business, boosted by the CFS Vitafor acquisition, and a 41% jump in Vanillin revenue (despite lower realizations) powered growth.

Strategic focus is on integrating high-value Blends/Vanillin and launching new specialty ingredients in FY26. **Outlook:** Management eyes faster Blends growth via expanded marketing & smart acquisitions, plus rising Vanillin volumes with better margins ahead.

Net Debt stands at Rs 519.7 Cr.